Want to see VBIO full AI Analyst Report?
VBIO Stock Chart & Stats
$0.16
>-$0.01(-2.18%)
At close: 4:00 PM EST
$0.16
>-$0.01(-2.18%)
Day’s Range― - ―
52-Week Range$2.05 - $78.75
Previous CloseN/A
VolumeN/A
Average Volume (3M)793.78K
Market Cap
$2.11M
Enterprise Value$24.70
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$17.41M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.74
Shares Outstanding887,590
10 Day Avg. Volume109,373
30 Day Avg. Volume793,783
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.49
Price to Sales (P/S)0.00
P/FCF Ratio-5.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe very low debt burden gives Valion Bio greater financial flexibility than a highly leveraged company. A relatively conservative capital structure can reduce interest pressure and preserve capacity to fund development, manufacturing, and commercialization initiatives as the business grows.
Positive Gross EconomicsPositive gross profit and a roughly 39% gross margin indicate that Valion Bio is generating some favorable economics at the product level despite its small revenue base. If revenue becomes more consistent, this gross-profit foundation could support operating leverage and improve funding efficiency.
Entolimod Platform And Manufacturing ProgressThe manufacturing scale-up and broader Entolimod applications strengthen Valion Bio’s platform potential across radiation preparedness and oncology supportive care. FDA Animal Rule development, Fast Track and Orphan Drug status, and owned manufacturing provide structural foundations for future commercialization, although outcomes remain uncertain.
Bears Say
Severe Operating LossesOperating expenses currently far exceed the company’s limited revenue base, producing exceptionally deep losses. This weak profitability reduces internal funding capacity and means Valion Bio must achieve substantial revenue expansion or cost improvement before its business model can become sustainably self-supporting.
Persistent Cash BurnOngoing negative operating and free cash flow shows that Valion Bio is not yet funding its operations internally. Continued burn can consume available resources and increase dependence on external capital, creating a durable constraint on development, manufacturing, and commercialization plans.
Dilutive And Cash-flow Burdens From FinancingThe structured financing supplies near-term cash but may increase future shareholder dilution and impose claims on operating value through preferred securities, warrants, and the long-term royalty. These obligations could reduce future cash retained by the business and reinforce dependence on additional funding.
Valion Bio News
VBIO FAQ
What was Valion Bio’s price range in the past 12 months?
Valion Bio lowest stock price was $2.05 and its highest was $78.75 in the past 12 months.
What is Valion Bio’s market cap?
Valion Bio’s market cap is $2.11M.
When is Valion Bio’s upcoming earnings report date?
Valion Bio’s upcoming earnings report date is Nov 13, 2026 which is in 51 days.
How were Valion Bio’s earnings last quarter?
Valion Bio released its earnings results on Aug 17, 2026. The company reported -$52.537 earnings per share for the quarter.
Is Valion Bio overvalued?
According to Wall Street analysts Valion Bio’s price is currently Overvalued.
Does Valion Bio pay dividends?
Valion Bio does not currently pay dividends.
What is Valion Bio’s EPS estimate?
Valion Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valion Bio have?
Valion Bio has 887,590 shares outstanding.
What happened to Valion Bio’s price movement after its last earnings report?
Valion Bio reported an EPS of -$52.537 in its last earnings report. Following the earnings report the stock price went down -4.26%.
Which hedge fund is a major shareholder of Valion Bio?
Currently, no hedge funds are holding shares in VBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valion Bio
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
VBIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.View all VBIO earnings summariesTechnical Analysis
Ownership Overview
8.26% Insiders
1.28% Mutual Funds
― Other Institutional Investors
90.46% Public Companies and
Individual Investors